Cloning & Mutagenesis Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 3.11 Billion
CAGR (2026-2031)	19.26%
Fastest Growing Segment	Mutagenesis Kits
Largest Market	North America
Market Size (2031)	USD 8.95 Billion

Market Overview

The Global Cloning & Mutagenesis Market is projected to grow from USD 3.11 Billion in 2025 to USD 8.95 Billion by 2031 at a 19.26% CAGR. The Global Cloning & Mutagenesis Market involves the deliberate manipulation of genetic material to create identical copies of DNA, cells, or organisms (cloning), or to introduce specific alterations within a genome (mutagenesis). This specialized biotechnology sector is primarily driven by continuous advancements in genetic engineering techniques, the increasing demand for personalized medicine and therapeutic development, and growing investment in fundamental biotechnology research across various applications, including agriculture and industrial bioprocesses.

According to the Biotechnology Innovation Organization (BIO), in 2024, venture capital investment in the U.S. bioscience industry, which provides foundational support for technologies such as cloning and mutagenesis, reached $26 billion. However, a significant challenge that could impede market expansion is the complex ethical and regulatory landscape governing genetic manipulation, which necessitates rigorous oversight and broad societal acceptance for widespread application.

Key Market Drivers

The increasing adoption of advanced gene editing technologies serves as a primary driver for the Global Cloning & Mutagenesis Market, enhancing the precision and efficiency of genetic manipulation. Innovations such as CRISPR-Cas systems continue to refine the ability to introduce specific alterations within genomes, enabling more targeted research and therapeutic development. These technological advancements provide researchers with powerful tools for gene knockout, gene insertion, and base editing, thereby accelerating scientific discovery and application. According to Cure., in March 2026, CRISPR Therapeutics announced it would raise an upsized $550 million through a convertible senior notes offering, highlighting significant investment in these core technologies. This funding supports ongoing innovation and broader commercialization efforts for gene editing platforms.

Concurrently, the growing demand for personalized medicine and therapeutics significantly influences the market by requiring highly specific genetic interventions tailored to individual patient profiles. Cloning and mutagenesis techniques are fundamental in developing these bespoke treatments, from creating disease models for drug screening to engineering therapeutic cells. This approach customizes medical treatments based on individual genetic, environmental, and lifestyle factors. According to The Personalized Medicine Coalition, in its May 2025 report to the FDA, 18 new personalized medicines and six new gene and cell-based therapies for genetic diseases and certain cancers were approved in 2024, demonstrating the tangible outputs of this demand. This trend underscores the essential role of genetic manipulation in advancing patient-specific healthcare solutions. The broader biopharma sector, critical to the cloning and mutagenesis market, saw substantial activity, with JPMorgan reporting biopharma licensing announced value of $82.7 billion in Q1 2026.

Download Free Sample Report

Key Market Challenges

The complex ethical and regulatory landscape governing genetic manipulation presents a significant impediment to the growth of the Global Cloning & Mutagenesis Market. This intricate environment creates substantial uncertainty for developers, leading to prolonged development timelines and elevated costs associated with ensuring compliance. Varying interpretations and stringent oversight mechanisms across different jurisdictions can also hinder international collaboration and market entry, further stifling innovation and commercialization of new genetic technologies.

The direct impact of this challenge is evident in the pace of product approvals and market access. For instance, according to the Alliance for Regenerative Medicine, the United States was only on pace for 4 to 5 cell and gene therapy approvals in 2025. This limited number of new market entrants, despite ongoing scientific advancements in genetic manipulation, underscores how rigorous and often protracted regulatory processes constrain the translation of research into commercially available products. Such a challenging environment can deter necessary investment, thereby slowing the expansion of critical applications within the cloning and mutagenesis sector.

Key Market Trends

Automation and digitalization of laboratory workflows are fundamentally reshaping the Global Cloning & Mutagenesis Market by enhancing operational efficiency and data integrity. The integration of robotic systems, advanced software, and cloud-based platforms allows for precise, repeatable execution of complex genetic manipulation protocols, significantly reducing manual errors and increasing throughput. This trend facilitates the handling of larger sample volumes and intricate experimental designs, which are crucial for drug discovery and synthetic biology applications. According to Thermo Fisher Scientific Inc., in its January 29, 2026, Q4 2025 earnings transcript, its Life Science Solutions segment, which includes tools for laboratory workflows, reported a 13% increase in revenue.

The development of high-throughput and seamless cloning methodologies represents another pivotal trend, enabling more rapid and efficient creation of recombinant DNA constructs without traditional laborious steps. These innovations allow researchers to quickly generate multiple gene variants and expression vectors for parallel screening, accelerating the pace of discovery and therapeutic development. The streamlined nature of these methods minimizes technical bottlenecks and expands the scope of complex genetic engineering projects. According to Sartorius AG, in its February 3, 2026, preliminary results for 2025, the Bioprocess Solutions Division, which provides technologies for biopharmaceutical production, achieved a 9.5% sales revenue increase in constant currencies. This reflects the demand for efficient and scalable solutions that underpin advanced biomanufacturing, heavily reliant on efficient cloning.

Segmental Insights

The Mutagenesis Kits segment is experiencing rapid expansion within the Global Cloning & Mutagenesis Market, emerging as its fastest-growing component. This accelerated growth is primarily driven by the kits' indispensable role in advanced biomedical research, particularly for functional studies, protein engineering, and the development of novel therapeutics. Mutagenesis kits enable precise and intentional alterations to DNA sequences, which is fundamental for understanding gene function, creating disease models, and developing gene therapies and personalized medicine. Furthermore, increasing investments in biotechnology research and development by pharmaceutical companies and academic institutions globally are fueling the adoption of these kits, as they streamline and enhance the efficiency of genetic manipulation experiments crucial for drug discovery and other applications.

Regional Insights

North America leads the global cloning and mutagenesis market, primarily due to its highly developed biotechnology ecosystem and extensive research infrastructure across academic and private institutions. The region benefits from a strong presence of pharmaceutical and biotechnology companies that actively engage in gene editing and molecular cloning studies. This dominance is further supported by significant investments in genetic engineering research and development, alongside a favorable legal and regulatory framework that facilitates the adoption of intricate technologies. For instance, regulatory bodies such as the U.S. Food and Drug Administration support the advancement and commercialization of related biotechnological innovations.

Recent Developments

In April 2026, Cartherics Pty Ltd. and Catalent Inc. announced an enhanced partnership directly relevant to advancements in the global cloning and mutagenesis market. The companies formalized an amended commercial license agreement. This agreement permits Cartherics to utilize a Catalent cGMP-compliant induced pluripotent stem cells (iPSC) line. The collaboration aims to facilitate the manufacture and commercialization of Cartherics' iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies, which rely heavily on sophisticated genetic engineering and cell modification techniques.
In August 2025, Replicate and Novo Nordisk entered into a multiyear research collaboration, impacting the global cloning and mutagenesis market. The agreement allows Novo Nordisk to leverage Replicate’s proprietary srRNA technology to develop innovative therapies. This collaboration is specifically aimed at addressing conditions such as obesity, type 2 diabetes, and other cardiometabolic diseases. Such partnerships are vital for advancing the application of genetic and synthetic biology tools in the discovery and development of new therapeutic agents.
In June 2025, eGenesis achieved a significant breakthrough in research within the cloning and mutagenesis market by successfully transplanting genetically modified pig kidneys into human recipients. One patient was sustained for 271 days without dialysis, establishing a new record, while a second recipient continued off dialysis following their June transplant. The company also secured FDA clearance for an expanded trial of this innovative procedure. This development underscores the advancing capabilities in xenotransplantation, a direct application of genetic modification and animal cloning techniques for human therapeutic purposes.
In January 2025, Bio-Rad Laboratories, Inc. introduced Nuvia wPrime 2A Media, a new product in the global cloning and mutagenesis market. This scalable weak anion exchange and hydrophobic interaction mixed-mode chromatography resin is designed for purifying biomolecules on both small and large scales. Partners involved in the resin's development successfully utilized it to eliminate host cell proteins, various molecular weight aggregates and impurities, DNA from monoclonal and bispecific antibodies, and adeno-associated virus. This launch provides crucial tools for researchers and manufacturers involved in genetic engineering and therapeutic development.

Key Market Players

Agilent Technologies Inc.
Eurofins Scientific SE
Sartorius AG
Collecta Inc.
Codex DNA Inc.
Lonza Group AG
Charles River Laboratories International Inc.
TransGene Biotech Co. Ltd.
Takara Bio, Inc.
Thermo Fisher Scientific Inc.

By Gene Type	By Product Type	By Technique	By Application	By End User	By Region
Standard Complex	Cloning Kits Mutagenesis Kits	Topo PCR Cloning Blunt End Cloning Seamless Cloning Site-Directed Mutagenesis Others	Gene Synthesis Gene Expression Gene Therapy Vaccine Research Others	Pharmaceutical & Biotechnology Companies Academic & Research Institutions Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cloning & Mutagenesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cloning & Mutagenesis Market, By Gene Type:

Standard
Complex

Cloning & Mutagenesis Market, By Product Type:

Cloning Kits
Mutagenesis Kits

Cloning & Mutagenesis Market, By Technique:

Topo PCR Cloning
Blunt End Cloning
Seamless Cloning
Site-Directed Mutagenesis
Others

Cloning & Mutagenesis Market, By Application:

Gene Synthesis
Gene Expression
Gene Therapy
Vaccine Research
Others

Cloning & Mutagenesis Market, By End User:

Pharmaceutical & Biotechnology Companies
Academic & Research Institutions
Others

Cloning & Mutagenesis Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cloning & Mutagenesis Market.

Available Customizations:

Global Cloning & Mutagenesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Cloning & Mutagenesis Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cloning & Mutagenesis Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Gene Type (Standard, Complex)

5.2.2. By Product Type (Cloning Kits, Mutagenesis Kits)

5.2.3. By Technique (Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, Others)

5.2.4. By Application (Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others)

5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)

5.2.6. By Region

5.2.7. By Company (2025)

5.3. Market Map

6. North America Cloning & Mutagenesis Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Gene Type

6.2.2. By Product Type

6.2.3. By Technique

6.2.4. By Application

6.2.5. By End User

6.2.6. By Country

6.3. North America: Country Analysis

6.3.1. United States Cloning & Mutagenesis Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Gene Type

6.3.1.2.2. By Product Type

6.3.1.2.3. By Technique

6.3.1.2.4. By Application

6.3.1.2.5. By End User

6.3.2. Canada Cloning & Mutagenesis Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Gene Type

6.3.2.2.2. By Product Type

6.3.2.2.3. By Technique

6.3.2.2.4. By Application

6.3.2.2.5. By End User

6.3.3. Mexico Cloning & Mutagenesis Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Gene Type

6.3.3.2.2. By Product Type

6.3.3.2.3. By Technique

6.3.3.2.4. By Application

6.3.3.2.5. By End User

7. Europe Cloning & Mutagenesis Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Gene Type

7.2.2. By Product Type

7.2.3. By Technique

7.2.4. By Application

7.2.5. By End User

7.2.6. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Cloning & Mutagenesis Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Gene Type

7.3.1.2.2. By Product Type

7.3.1.2.3. By Technique

7.3.1.2.4. By Application

7.3.1.2.5. By End User

7.3.2. France Cloning & Mutagenesis Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Gene Type

7.3.2.2.2. By Product Type

7.3.2.2.3. By Technique

7.3.2.2.4. By Application

7.3.2.2.5. By End User

7.3.3. United Kingdom Cloning & Mutagenesis Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Gene Type

7.3.3.2.2. By Product Type

7.3.3.2.3. By Technique

7.3.3.2.4. By Application

7.3.3.2.5. By End User

7.3.4. Italy Cloning & Mutagenesis Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Gene Type

7.3.4.2.2. By Product Type

7.3.4.2.3. By Technique

7.3.4.2.4. By Application

7.3.4.2.5. By End User

7.3.5. Spain Cloning & Mutagenesis Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Gene Type

7.3.5.2.2. By Product Type

7.3.5.2.3. By Technique

7.3.5.2.4. By Application

7.3.5.2.5. By End User

8. Asia Pacific Cloning & Mutagenesis Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Gene Type

8.2.2. By Product Type

8.2.3. By Technique

8.2.4. By Application

8.2.5. By End User

8.2.6. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Cloning & Mutagenesis Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Gene Type

8.3.1.2.2. By Product Type

8.3.1.2.3. By Technique

8.3.1.2.4. By Application

8.3.1.2.5. By End User

8.3.2. India Cloning & Mutagenesis Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Gene Type

8.3.2.2.2. By Product Type

8.3.2.2.3. By Technique

8.3.2.2.4. By Application

8.3.2.2.5. By End User

8.3.3. Japan Cloning & Mutagenesis Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Gene Type

8.3.3.2.2. By Product Type

8.3.3.2.3. By Technique

8.3.3.2.4. By Application

8.3.3.2.5. By End User

8.3.4. South Korea Cloning & Mutagenesis Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Gene Type

8.3.4.2.2. By Product Type

8.3.4.2.3. By Technique

8.3.4.2.4. By Application

8.3.4.2.5. By End User

8.3.5. Australia Cloning & Mutagenesis Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Gene Type

8.3.5.2.2. By Product Type

8.3.5.2.3. By Technique

8.3.5.2.4. By Application

8.3.5.2.5. By End User

9. Middle East & Africa Cloning & Mutagenesis Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Gene Type

9.2.2. By Product Type

9.2.3. By Technique

9.2.4. By Application

9.2.5. By End User

9.2.6. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Cloning & Mutagenesis Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Gene Type

9.3.1.2.2. By Product Type

9.3.1.2.3. By Technique

9.3.1.2.4. By Application

9.3.1.2.5. By End User

9.3.2. UAE Cloning & Mutagenesis Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Gene Type

9.3.2.2.2. By Product Type

9.3.2.2.3. By Technique

9.3.2.2.4. By Application

9.3.2.2.5. By End User

9.3.3. South Africa Cloning & Mutagenesis Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Gene Type

9.3.3.2.2. By Product Type

9.3.3.2.3. By Technique

9.3.3.2.4. By Application

9.3.3.2.5. By End User

10. South America Cloning & Mutagenesis Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Gene Type

10.2.2. By Product Type

10.2.3. By Technique

10.2.4. By Application

10.2.5. By End User

10.2.6. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Cloning & Mutagenesis Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Gene Type

10.3.1.2.2. By Product Type

10.3.1.2.3. By Technique

10.3.1.2.4. By Application

10.3.1.2.5. By End User

10.3.2. Colombia Cloning & Mutagenesis Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Gene Type

10.3.2.2.2. By Product Type

10.3.2.2.3. By Technique

10.3.2.2.4. By Application

10.3.2.2.5. By End User

10.3.3. Argentina Cloning & Mutagenesis Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Gene Type

10.3.3.2.2. By Product Type

10.3.3.2.3. By Technique

10.3.3.2.4. By Application

10.3.3.2.5. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Cloning & Mutagenesis Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Agilent Technologies Inc.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Eurofins Scientific SE

15.3. Sartorius AG

15.4. Collecta Inc.

15.5. Codex DNA Inc.

15.6. Lonza Group AG

15.7. Charles River Laboratories International Inc.

15.8. TransGene Biotech Co. Ltd.

15.9. Takara Bio, Inc.

15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Cloning & Mutagenesis Market in 2025?

Which is the dominating region in the Global Cloning & Mutagenesis Market?

Which is the fastest growing segment in the Global Cloning & Mutagenesis Market?

What is the expected growth rate of the Global Cloning & Mutagenesis Market?